Amniotics

Less than 1K followers

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.

All

Research

Press releases

ShowingAll content types

Regulatory press release9/23/2024, 11:30 AM

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Press release8/20/2024, 11:27 AM

Redeye: Amniotics H1 2024 - Merger with Magle

Regulatory press release8/6/2024, 8:45 AM

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release8/6/2024, 6:45 AM

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Regulatory press release7/1/2024, 3:30 PM

Amniotics publishes merger document regarding the merger with Magle Group

Regulatory press release5/30/2024, 6:05 PM

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Regulatory press release5/30/2024, 6:00 PM

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Regulatory press release5/21/2024, 7:50 PM

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Regulatory press release3/22/2024, 6:40 AM

Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed

Regulatory press release3/21/2024, 5:00 PM

Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement

Regulatory press release3/11/2024, 3:00 PM

Amniotics announces the outcome of the exercise of warrants series TO 3

Regulatory press release2/26/2024, 7:30 AM

The exercise period for warrants series TO 3 in Amniotics begins today

Press release2/26/2024, 6:57 AM

Redeye: Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Regulatory press release2/22/2024, 2:05 PM

Amniotics AB (publ) Report for the fourth quarter 2023.

Press release12/21/2023, 1:16 PM

Information about the Annual General Meeting and appointed Nomination Committee of Amniotics

Regulatory press release12/14/2023, 10:20 AM

Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Press release11/28/2023, 7:30 AM

Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Regulatory press release11/27/2023, 7:00 AM

Amniotics AB (publ) Report for the third Quarter 2023

Press release11/23/2023, 11:00 AM

Renewed GMP certification

Regulatory press release11/20/2023, 2:40 PM

Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Forum discussions

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based ...

10/17/2022, 7:58 AM

by Olivier A. de Goeij

0

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.